PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Results 1 - 20 of 126 : 1 2 3 4 5 6 7 Next »

Recs

0
Member Avatar OklaBoston (65.86) Submitted: 4/10/2016 6:39:35 PM : Outperform Start Price: $3.28 PDLI Score: -2.86

Senior officer open market buying since this fell below $10.00.

Recs

0
Member Avatar TomKnighton (46.11) Submitted: 3/19/2016 9:16:36 AM : Outperform Start Price: $3.16 PDLI Score: +0.24

Great profit, good price to book ratio (though price to tangible book ratio is worse than I'd like), and seemingly low overhead all in all.

Not too shabby.

Recs

1
Member Avatar LarkinSoft (99.81) Submitted: 10/29/2015 11:07:50 AM : Outperform Start Price: $4.45 PDLI Score: -26.84

Screened result of <=15 P/E, yields between 8-20%. Then, Current Yield divided by square root of price, adjusted for P/E, LT Debt ratio, and price % above 12-month low. Pick is within top 15 of resulting list. Premise: stock may or may not grow, but yields should more than compensate.

Recs

0
Member Avatar healthcarevalue (97.60) Submitted: 7/25/2015 9:29:58 PM : Outperform Start Price: $5.51 PDLI Score: -41.33

PDL BioPharma, Inc. (PDLI) - price/earnings ratio of 3.4 shows a stock priced very cheaply. Debt/equity of 0.62 is not too bad. Return on Invested Capital (ROIC) these past TTM of 41.87 is simply amazing. Market cap of 989.47M leaves room for potential acquisition as a possibility in the future.

Recs

1
Member Avatar racoveanul (74.51) Submitted: 6/28/2015 5:35:54 AM : Outperform Start Price: $5.91 PDLI Score: -44.66

PDL BIOPHARMA, ticker PDLI, has a TTM ROE calculated by Zacks of 82,89%. It's one of my LONG picks.

Recs

1
Member Avatar mccarrara (37.33) Submitted: 6/3/2015 11:53:00 AM : Outperform Start Price: $5.99 PDLI Score: -43.57

low PE

Recs

1
Member Avatar savolk77 (24.50) Submitted: 3/4/2015 1:12:05 AM : Outperform Start Price: $6.35 PDLI Score: -47.32

Nice earnings history last few years, solid fundamentals, could be ready to pop.

Recs

2
Member Avatar jason418 (< 20) Submitted: 1/4/2015 2:14:57 AM : Outperform Start Price: $6.70 PDLI Score: -52.89

Currently, PDLI has about two years of decent earning to continue to build a portfolio of intellectual property and interest income. Over the last three years, they have negotiated an average of 4 deals per year with other companies and have averaged an impressive IRR. The uncertainty priced into the stock is based upon whether or not they can continue that same performance. I believe the track record is good so far and is an excellent indicator of things to come. Despite some debt, they're in an excellent financial position to capitalize on many opportunities. The biggest downside is the possibility that they may reduce or cut their dividend altogether. I think if you're a long-term investor, however, you'll see their current strategy payoff in the form of solid revenue growth. You just have to ride out a couple years of investments.

Recs

1
Member Avatar aa119634 (35.99) Submitted: 9/24/2014 12:43:14 PM : Outperform Start Price: $6.59 PDLI Score: -54.82

On-going royalties of .60 per share should be maintainable. With no price appreciation you earn 7.8% just sitting with the stock. If it gets close to 9 consider selling and buying back again if it gets under 8.

Recs

1
Member Avatar johnclanaro (< 20) Submitted: 8/19/2014 8:47:46 PM : Outperform Start Price: $8.17 PDLI Score: -64.48

2d qtr beats on eps, beats on revenue. yields 6.44% at a price of 9.55 per share.

Recs

1
Member Avatar Cabzx (53.24) Submitted: 8/17/2014 1:43:15 PM : Outperform Start Price: $8.06 PDLI Score: -64.64

The large Debt/Equity maybe a turnoff for some, but the company has solid revenues, consistently beating the industry. It has a very high coverage and makes for a consistent buy.

Recs

1
Member Avatar NorbertV (< 20) Submitted: 1/28/2014 5:12:41 PM : Outperform Start Price: $7.37 PDLI Score: -72.25

2 years 33% gain plus excellent dividend. P/E at 5 right now no reason it shouldn't continue up.

Recs

1
Member Avatar lnlrmtg (< 20) Submitted: 1/8/2014 2:31:12 AM : Outperform Start Price: $7.15 PDLI Score: -67.21

fundamentals

Recs

1
Member Avatar Haugurafpeningum (26.67) Submitted: 1/5/2014 2:24:06 PM : Outperform Start Price: $7.14 PDLI Score: -67.10

porte and zz 1

Recs

0
Member Avatar Stregachess (< 20) Submitted: 10/3/2013 12:07:46 AM : Underperform Start Price: $6.45 PDLI Score: +72.08

Analyst love this stock but the IP can't be controlled they are in for a rough ride. Without patent protection it's all just a dream.

Recs

1
Member Avatar tgainesphd (52.58) Submitted: 4/18/2013 8:01:13 PM : Outperform Start Price: $5.85 PDLI Score: -78.25

Good growth potential.

Recs

1
Member Avatar Aquinas31 (25.96) Submitted: 4/3/2013 4:56:19 PM : Outperform Start Price: $5.73 PDLI Score: -76.27

Dividends going up, probably hits 8+ by 4th quarter

Recs

2
Member Avatar FoxForce5contest (< 20) Submitted: 8/18/2012 9:18:30 PM : Outperform Start Price: $5.42 PDLI Score: -85.64

on 8-18-12 Momentum21 picked PDLI

Recs

1
Member Avatar myfairshare (< 20) Submitted: 8/17/2012 6:04:53 PM : Outperform Start Price: $5.42 PDLI Score: -85.64

I think the royalties are the best position to be in, for the pharmaceutical plays.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:35:17 PM : Outperform Start Price: $4.96 PDLI Score: -85.51

Biotech with solid pipeline

Featured Broker Partners